Search Results 2081-2090 of 20130 for Receptor

  1. Movement disorders - Doctors and departments - Mayo Clinic

    Areas of focus: Movement disorder, Dystonia, NMDA receptor antibody encephalitis, Myelin oligodendrocyte glycoprotein antibody-associat...ed disease, Stiff ...

  2. Movement disorders - Doctors and departments - Mayo Clinic

    Areas of focus: Movement disorder, Dystonia, NMDA receptor antibody encephalitis, Myelin oligodendrocyte glycoprotein antibody-associat...ed disease, Stiff ...

  3. Movement disorders - Doctors and departments - Mayo Clinic

    Areas of focus: Movement disorder, Dystonia, NMDA receptor antibody encephalitis, Myelin oligodendrocyte glycoprotein antibody-associat...ed disease, Stiff ...

  4. Regenerative Sciences Students Show Resilience Despite Research Disruptions Due to COVID-19 - News Archive

    D. in virology and gene therapy. Her research seeks to develop and optimize chimeric antigen receptor-T cell therapy (CAR-T cell therapy). CAR ...

  5. Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    The vasopressin V2 receptor antagonist lixivaptan has also been shown to ameliorate polycystic disease manifestations in animal models of the disease.

  6. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization - Radiation therapy within 4 weeks (2 ...

  7. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) - Mayo Clinic

    * received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication who have not ...

  8. Publications - Jeffrey E. Johnson, M.D. - Mayo Clinic

    ... receptor-positive breast cancer patients. Breast Cancer Res Treat. 2020 Nov; 184 (1):63-74 Epub 2020 Aug 09. View PubMed; Bloom MB, Johnson J, Volod O, Lee EY ...

  9. Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients with Early-Stage Breast Cancer that was Removed by Surgery - Mayo Clinic

    Non-hormone-sensitive breast cancer (estrogen and progesterone receptor negative (ER- and PR-) or; Grade III histology or; Oncotype recurrence score > 25 or.

  10. Andrew C. Greenlund, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    PhD - Immunology - Doctoral Dissertation: Stat1 Recruitment by Dimerized, Tyrosine Phosphorylated IFNy ReceptorsWashington University School of Medicine.